The active ingredient of the veterinary product is nosiheptide, a bicyclic thiopeptide produced by the fungus Streptomyces actuosus. Nosiheptide has a marked antibacterial effect on Gram-positive bacteria and some Gram-negative bacteria, including all types of Clostridium spp., Escherichia coli, Staphylococcus aureus, Streptococcus pyogenes haemolyticus, Streptococcus viridans, Streptococcus faecalis, Diplococcus pneumoniae, Salmonella spp. and other. Does not have an adverse effect on obligate micro-organisms in the gastrointestinal tract.
The mechanism of antibacterial action of the veterinary product is to disrupt bacterial protein synthesis; it inhibits the function of elongation factors Tu and G and significantly reduces guanosine penta- and tetraphosphate synthesis in response to the stringent factor. This involves specific pentose methylation of the 23-s ribosome. Nosiheptide acts on the 50-s ribosomal subunits and binds the 23-s p-RNA complex to the L11 ribosomal protein.
When administered orally, nosiheptide is not absorbed from the gastrointestinal tract and forms a high concentration in the lumen. Nosiheptide does not accumulate in tissues and is excreted from the body unchanged.
The veterinary product is low-toxic, in the recommended doses has no mutagenic, sensitizing, embryotoxic and teratogenic effect, has no adverse effect on the quality of meat products.
